Case report of the patient with erythrocytosis and secondary arterial hypertension associated with hormone replacement therapy for gender reassignment


DOI: https://dx.doi.org/10.18565/therapy.2020.3.111-116

Minyakova E.V., Zhapueva M.H., Grishina I.S., Kokorin V.A.

1 N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia, Moscow; 2 Municipal Clinical Hospital №15 named after O.M. Filatov of Moscow Healthcare Department
In many countries, there is upward trend in the transsexuals and transgender sex change of both transition from male to female (MtF) and from female to male (FtM). Increasing of the transgender patients dictates to the modern doctor different conditions for diagnostic search and requires a consideration of fact in gender change in the choice of further management.
This article describes the clinical case of a patient in the hormonal phase of FtM transgender transition with hyperandrogenism of unverified origin. The reception of replacement therapy with exogenous testosterone was complicated by the erythrocytosis occurrence and secondary arterial hypertension. This clinical case is interesting not only from the point of view to determine further therapeutic tactics, but also by particular ethical approach of the medical personnel to transgender patient maintenance.
Keywords: erythrocytosis, аndrogenotherapy, transgender, gender reassignment, arterial hypertension
Read entire article

Literature


  1. Стандарты медицинской помощи транссексуалам, трансгендерам и гендерно неконформным индивидуумам. Всемирная профессиональная ассоциация по здоровью транссексуалов. 2013. Доступ по ссылке: https://www.wpath.org/media/cms/Documents/SOC%20v7/SOC%20V7_Russian.pdf (дата обращения – 17.04.2020). [Standards of care for the health of transsexual, transgender, and gender nonconforming people. The World Professional Association for Transgender Health. 2013. Available at: https://www.wpath.org/media/cms/Documents/SOC%20v7/SOC%20V7_Russian.pdf (date of access – 17.04.2020) (In Russ.)].

  2. Brown G.R. Гендерная дисфория и транссексуализм. Справочник MSD. 2019. Доступ по ссылке: https://www.msdmanuals.com/ru/дома/психические-расстройства/сексуальность-и-половые-расстройства/гендерная-дисфория-и-транссексуализм (дата обращения - 17.04.2020). [Brown G.R. Gender dysphoria and transsexual. MSD handbook. 2019. Available at: https://www.msdmanuals.com/ru/дома/психические-расстройства/сексуальность-и-половые-расстройства/гендерная-дисфория-и-транссексуализм (date of access – 17.04.2020) (In Russ.)].

  3. Byne W., Karasic D.H., Coleman E. et al. Gender dysphoria in adults: an overview and primer for psychiatrists. Transgend Health. 2018; 3(1): 57–70. doi: 10.1089/trgh.2017.0053.

  4. Богданова П.С., Карева М.А. Синдром гиперандрогении у девочек пубертатного возраста. Проблемы эндокринологии. 2010; 56(6): 48–54. [Bogdanova P.S., Kareva M.A. Syndrome of hyperandrogenism in girls of pubertal age. Problemy endokrinologii. 2010; 56(6): 48–54 (In Russ.)].

  5. Меликова А.В. Гиперандрогения: мифы и реальность. Эффективная фармакотерапия. Эндокринология. 2018; 3(26): 18–23. [Melikova A.V. Hyperandrogenia: myths and reality. Effektivnaya farmakoterapiya. Endokrinologiya. 2018; 3(26): 18–23 (In Russ.)].

  6. Vigen R., O’Donnell C.I., Baron A.E. et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013; 310(17): 1829–36. doi: 10.1001/jama.2013.280386.

  7. Schiffer L., Kempegowda P., Arlt W., O’Reilly M.W. Mechanisms in endocrinology: the sexually dimorphic role of androgens in human metabolic disease. Eur J Endocrinol. 2017; 177(3): R125–R143. doi: 10.1530/EJE-17-0124.

  8. Ohlander S.J., Varghese B., Pastuszak A.W. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018; 6(1): 77–85. doi: 10.1016/j.sxmr.2017.04.001.

  9. Fernandez-Balsells M.M., Murad M.H., Lane M. et al. Adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2010; 95(6): 2560–75. doi: 10.1210/jc.2009-2575.

  10. Braun H., Nash R., Tangpricha V. et al. Cancer in transgender people: evidence and methodological considerations. Epidemiol Rev. 2017; 39(1): 93–107. doi: 10.1093/epirev/mxw003.

  11. Poteat T., Scheim A., Xavier J. et al. Global epidemiology of HIV infection and related syndemics affecting transgender people. J Acquir Immune Defic Syndr. 2016; 72 (Suppl 3): S210–S219. doi: 10.1097/QAI.0000000000001087.


About the Autors

Evgeny V. Minyakova, student of the faculty of medicine of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityanova Str. Tel.: +7 (919) 722-00-30. E-mail: jeniya09@mail.ru
Marietta H. Zhapueva, MD, cardiologist of the 1st cardiology department of Municipal clinical hospital No. 15 named after O.M. Filatov of Moscow Healthcare Department. Address: 111539, Moscow, 23 Veshnyakovskaya Str. Tel.: +7 (967) 259-56-44. E-mail: zhapueva.mareta@mail.ru
Irina S. Grishina, MD, head of the 1st cardiology Department of Municipal clinical hospital No. 15 named after O.M. Filatov of Moscow Healthcare Department. Address: 111539, Moscow, 23 Veshnyakovskaya Str. Tel.: +7 (916) 632-45-34.
Valentin A. Kokorin, PhD, associate professor of the Department of hospital therapy No 1 of faculty of medicine of N.I. Pirogov Russian National Research Medical University of the Ministry of Healthcare of Russia. Address: 117997, Moscow, 1 Ostrovityanova Str. E-mail: valentinkokorin@yahoo.com. ORCID: 0000-0001-8614-6542.


Similar Articles

Back to Content

Бионика Медиа